THE BEST CELLS MAKE
THE BEST CURES
Recent years have demonstrated explosive growth for cell therapies leading to aggressive pipeline projections and a critical need for complex cell engineering capabilities.
The Artisan Approach
Advanced cell therapy applications require the ability to engineer the target cell genome with custom modifications, at high efficiencies and on-target precision, in a clinically compatible process on ambitious timelines.
The Artisan Value
A designer cell engineering and big data analysis platform to more rapidly generate safer and more efficacious cell therapies.
High-Efficiency, Customizable Workflows:
Cell engineering processes designed to take you from target discovery to the clinic
Expert Editing Systems:
Delivering cells with custom modifications matched to the technical specifications of your application
Modeling and Machine Learning Core:
Leveraging big data and advanced mathematics to optimize cell therapy design and build
Advanced Quality Control Platform:
State-of-the art microscopy, imaging, NGS, single cell, and live cell analysis methodologies
Artisan builds and tests designer cells.
Chief Executive Officer
Ryan T. Gill is an experienced executive, company builder, strategist, and leader of diverse technical teams. He currently serves as CEO and Board Member at Artisan bio where he is responsible for all aspects of Artisan's vision to design, build, and deliver precisely engineered cells for next-generation therapeutic applications.
Over the past 2 decades, Ryan has envisioned and built a range of internationally recognized efforts in the field of genome engineering, including roles as CEO, CSO, and Board Member at INSCRIPTA, founder and company formation at Biota, Inc., founder, advisor, and Board Member at Opxbio along with his academic roles in building a world-class synthetic biology group at the University of Colorado and subsequently at the Novo Nordisk Foundation Center for Biosustainablity in Denmark.
Ryan is the inventor on foundational patents for Artisan, as well as both INSCRIPTA and Opxbio, and has led a total of 30+ patents, 100+ peer reviewed publications, and dozens of invited and keynote presentations.
Chief Technology Officer
Tanya is a seasoned executive-level professional with a unique combination of experiences including technical, operational, and business leadership. Ventures include cell engineering startups with a variety of applications (cell therapies, biofuels, and biochemicals) and life sciences tools including instrumentation, reagent development, and software engineering. Prior to Artisan, Tanya was the co-Founder, CTO, and VP of Applications at INSCRIPTA and Director of Technology at OPXbio.
Tanya is the inventor on 20+ patent filings across a range of applications including metabolic and genome engineering of complex phenotypes and engineering novel endonucleases for CRISPR-based editing.
VP Cell Technologies and Entrepreneur in Residence
Nick is an experienced cell and gene therapy executive, innovator, and people leader. He has over 15 years experience developing an assortment cell and gene based therapies and associated technologies, including leadership roles at BlueRock Therapeutics, the Center for Commercialization of Regenerative Medicine (CCRM), and the Center for Advanced Therapeutic Cell Technologies. Nicks global experience includes time living and working in Canada, Switzerland, Australia, and New Zealand, engaging with a diverse assortment of partners, colleagues, and clients from industry and academia.
General Manager, Artisan Development Labs
Erik has an extensive financial and accounting background spanning 17 years and specializes in turning complicated financial data into meaningful information for effecting decision making. His expertise includes financing, controls and compliance, finance and treasury management, SEC and financial reporting and investor relations. Prior to Artisan, Erik served as VP of Finance at Inscripta, Head of Financial Reporting Operations at Metropolitan Merchant Capital and Controller at OPX Biotechnologies.
Director of Mammalian Synthetic Biology
Roland has 13+ years of experience in manipulation and editing of eukaryotic and human cell lines. Roland has direct experience with adapting CRISPR workflows to a variety of cell lines including T-cells, iPSC’s, and cancer cells to name a few and has worked with both primary and model cell lines for therapeutic applications. Prior to joining Artisan, Roland was the technical lead at the Cell Architecture Lab at DTU where he led the development efforts for next-generation T-cell therapeutics.
The Artisan team is passionate about crafting customized cell engineering solutions to solve the most challenging problems in human health applications. We believe that by leveraging rapid advances in DNA reading and writing technologies at the interface of engineering and biology we will deliver more efficacious and safe cell products to the market.
COME JOIN OUR TEAM!
Scientific Advisory Board
Rob Chess is a serial entrepreneur in the life sciences field. He currently is Chairman of NektarTherapeutics, (NASDAQ:NKTR), a health care biotechnology company, is lead director of Twist Biosciences (NASDAQ:TWST), which produces synthetic genes using an innovative high-throughput silicon-based manufacturing process, and is a co-founder, former Chairman, and a Board member of Biota Technologies, which is pioneering DNA sequencing for optimizing oil and gas production. Rob joined Nektar as its first non-founder employee in 1991 and led the company as CEO through 1999 and as Chairman since then. Robco-founded and was President of Penederm, a dermatology company that went public and was acquired by Mylan Laboratories, and was the start-up CEO and later Chairman of OPX Biotechnologies, a renewable chemicals company which was sold to Cargill. He started his career in the technology field and held management positions at Intel and Metaphor Computer Systems (later acquired by IBM). Rob served on the White House Staff in the first Bush Administration as a White House Fellow and Associate Director of the White House Office of Economic and Domestic Policy. He is a lecturer at the Stanford Graduate School of Business, where he teaches courses in health care and entrepreneurship. Rob received a BS in engineering with honors from Caltech and an MBA from Harvard.
Robert Deans, Ph.D., is a serial entrepreneur who has deep expertise in the cell and gene therapy space. He is currently CSO at Synthego, a leading CRISPR company focused on developing and deploying Full Stack Genome Engineering solutions. Prior to Synthego, Bob served as CTO of Bluerock, where he was responsible for implementing a novel induced pluripotent stem cell production platform. He has more than 25 years of experience in stem cell therapeutics, including hematopoietic as well as mesenchymal stem cell (MSC) cells and gene therapy approaches, as well as translational science and global regulatory expertise. Dr. Deans previously served as CSO of Rubius Therapeutics, where he was responsible for the development of a gene-engineered red cell therapeutics platform. He holds a B.S. from the Massachusetts Institute of Technology and a Ph.D. in microbiology from the University of Michigan.
Professor Lars Nielsen leads the development of experimental and computational tools to analyze and design complex biological systems at the University of Queensland in Australia and as the CSO of the Novo Nordisk Center for Biosustainability in Denmark. Professor Nielsen’s studies of biological systems as diverse as mammalian, bacteria, baker's yeast, and sugarcane has attracted industrial partnerships with companies including Dow, Metabolix, Amyris, LanzaTech, Boeing, Virgin Australia, and GE. Professor Nielsen is also applying system analysis and design approaches to tissue engineering including novel strategies for generating microtissues for drug screening and using stem cells to produce red and white blood cells for transfusion. Professor Nielsen has been granted patents in the fields of stem cells and metabolic engineering. Hewason the Scientific Advisory Board of InSphero (2009–2015), a company commercializing microtissue technology originating in the Nielsen laboratory, is an editorial board member of a wide variety of scientific journals and holds several major awards in his field.
Dr. Palsson is the GallettiProfessor of Bioengineering, the Principal Investigator of the Systems Biology Research Group in the Department of Bioengineering, and Professor of Pediatrics at the University of California, San Diego. He is also the CEO of the Novo Nordisk Center for Biosustainability in Denmark, working in this capacity since 2011. He has co-authored more than 450 peer-reviewed research articles and has authored four textbooks. His research includes the development of methods to analyze metabolic dynamics (flux-balance analysis, and modal analysis), and the formulation of complete models of selected cells (the red blood cell, E. coli, CHO cells, and several human pathogens). He sits on the editorial broad of several leading peer-reviewed microbiology, bioengineering, and biotechnology journals. He is the author of over 40 U.S. patents, the co-founder of several biotechnology companies, and holds several major biotechnology awards.
XSeed Capital believes in the creative destruction unleashed by technological innovators. Our portfolio companies boast significant differentiation that creates unique unique customer value.
363 Centennial Parkway, Suite 310, Louisville, CO 80027
Ole Maaløes Vej 3, 2200 København, Denmark